A Novel Method of Resistance for Influenza Against a Channel-Blocking Antiviral Drug

Proteins: Structure, Function and Genetics

Volumn 55, Issue 2, 2004, Pages 251-257

  Astrahan, Peleg ^a   Kass, Itamar ^a   Cooper, Matthew A ^b,c   Arkin, Isaiah T ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Akubio Ltd   (United Kingdom)

Author keywords

Antiviral; Channel blocker; Influenza; Ion channel; Protein structure

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ION CHANNEL;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; INFLUENZA VIRUS; NONHUMAN; POROSITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTON TRANSPORT; VIRUS RESISTANCE; VIRUS STRAIN;

AMANTADINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE;

EID: 1842427673     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.20018     Document Type: Article

References (26)

1. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G. Characterization of 2 Influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 2002;186:1074-1080.
2. Molla A, Kati W, Carrick R, Steffy K, Shi Y, Montgomery D, Gusick N, Stoll, VS, Stewart KD, Ng TI, Maring C, Kempf DJ, Kohlbrenner, W. In vitro selection and characterization of Influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002;76:5380-5386.
3. Englund JA. Antiviral therapy of influenza. Semin Pediatr Infect Dis 2002;13:120-128.
4. Lamb RA, Lai CJ, Choppin PW. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc Natl Acad Sci USA 1981;78:4170-4174.
5. Parks GD, Hull JD, Lamb RA. Transposition of domains between the M2 and HN viral membrane proteins results in polypeptides which can adopt more than one membrane orientation. J Cell Biol 1989;109:2023-2032.
6. Sakaguchi T, Tu Q, Pinto LH, Lamb RA. The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. Proc Natl Acad Sci USA 1997;94:5000-5005.
7. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992;69:517-528.
8. Wang C, Lamb RA, Pinto LH. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys J 1995;69:1363-1371.
9. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985;4:3021-3024.
10. Kovacs FA, Cross TA. Transmembrane four-helix bundle of Influenza A M2 protein channel: structural implications from helix tilt and orientation. Biophys J 1997;73:2511-2517.
11. Kovacs FA, Denny JK, Song Z, Quine JR, Cross TA. Helix tilt of the M2 transmembrane peptide from Influenza A virus: an intrinsic property. J Mol Biol 2000;295:117-125.
12. Wang J, Kim S, Kovacs F, Cross TA. Structure of the transmembrane region of the M2 protein H(+) channel. Protein Sci 2001;10: 2241-2250.
13. Kukol A, Adams PD, Rice LM, Brunger AT, Arkin TI. Experimentally based orientational refinement of membrane protein models: A structure for the Influenza A M2 H+ channel. J Mol Biol 1999;286:951-962.
14. Nishimura K, Kim S, Zhang L, Cross TA. The closed state of a H+ channel helical bundle combining precise orientational and distance restraints from solid state NMR. Biochemistry 2002;41: 13170-13177.
15. Cooper MA, Hansson A, Lofas S, Williams DH. A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal Biochem 2000;277:196-205.
16. Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Hamalainen M, Karlsson R. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J Med Chem 2000;43:1986-1992.
17. Duff KC, Ashley RH. The transmembrane domain of Influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 1992;190:485-489.
18. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of Influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993;67:5585-5594.
19. Smart OS, Neduvelil JG, Wang X, Wallace BA, Sansom MS. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J Mol Graph 1996;14:354-360.
20. Tang Y, Zaitseva F, Lamb RA, Pinto LH. The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue. J Biol Chem 2002;277:39880-39886.
21. Sansom MS, Kerr ID, Smith GR, Son HS. The Influenza A virus M2 channel: a molecular modeling and simulation study. Virology 1997;233:163-173.
22. Smondyrev AM, Voth GA. Molecular dynamics simulation of proton transport through the Influenza A virus M2 channel. Biophys J 2002;83:1987-1996.
23. Chang NS, French RJ, Lipkind GM, Fozzard HA, Dudley S Jr. Predominant interactions between mu-conotoxin Arg-13 and the skeletal muscle Na+ channel localized by mutant cycle analysis. Biochemistry, 1998;37:4407-4419.
24. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994;68:1551-1563.
25. Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of Influenza A viruses. Virology 1992;191:541-549.
26. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-38.